-- Mayne Pharma acquisition -- 25.5 percentage points;
-- Favorable volume/mix in the legacy Hospira business -- 6.1 percentage
points;
-- Favorable foreign currency translation -- 1.7 percentage points; and
-- Favorable pricing in the U.S. -- 0.4 percentage point.
A schedule detailing net sales by product line for the three- and 12-month periods ended Dec. 31, 2007 and 2006, is attached to this press release.
In conjunction with the previous table, the following summarizes
selected financial results for the fourth quarter of 2007 compared to the
same period in 2006:
In $ millions GAAP Adjusted*
Three Months Ended Three Months Ended
Dec. 31, Dec. 31,
---------------- % ---------------- %
2007 2006 Change 2007 2006 Change
------ ------ ------ ------ ------ ------
Gross Profit $338.6 $250.3 35.3% $363.7 $258.9 40.5%
R&D $53.8 $55.1 (2.4)% $53.4 $54.6 (2.1)%
S,G&A $167.7 $111.7 50.2% $156.7 $106.2 47.5%
Income from
Operations $114.0 $73.6 54.9% $153.6 $98.1 56.6%
Statistics (as a % of Net Sales)
--------------------------------
Gross Profit 35.8% 35.4% 38.4% 36.6%
R&D 5.7% 7.8% 5.6% 7.7%
S,G&A 17.7% 15.8% 16.6% 15.0%
Income from
Operations 12.0% 10.4% 16.2% 13.9%
Results under U.S. Generally Accepted Accounting Principles (GAAP) include items as detailed in the schedules attached to this press release.
The year-over-year improvement in adjusted* gross profit as a
percentage of net sales, or adjusted*
'/>"/>
| SOURCE Hospira, Inc. Copyright©2008 PR Newswire. All rights reserved |